about

Our Company

Global Medical Aesthetics
From Clinic to Home

Powered by three proprietary platforms, we bring clinical-grade anti-aging from the doctor's office to daily home care.

MEDIFAB | From Clinic to Home

We pioneer science-driven aesthetics and therapeutics, translating proprietary ingredient platforms into professional-grade anti-aging solutions.

Bridging clinical therapy and aesthetic medicine

MEDIFAB leverages three proprietary ingredient platforms to deliver total anti-aging performance—from the clinic to the home.

history

Our journey

2025

res novae Scalp MD Solution

MFDS approval · FDA registration · EU MDR Class I CE Marking

Approval of clinical trial protocol for Chitosan LTG-S medical device

2024

Launched skin booster res novae Crystal Plus

Launched home-care beauty device res novae Core Impact

2023

Launched res novae brand

Obtained Thailand regulatory approval

2022

Applied for government R&D project

Husteon Nasal MFDS approval

2021

Selected as Innovative Enterprise National Representative 1000

Husteon Mesh MFDS approval

Launched Echrever

2020

Obtained medical device manufacturing license

Obtained Husteon export license

Government-supported R&D project

Obtained ISO 13485 certification

2019

Government-supported R&D project

ISO 9001, ISO 14001 certification

2018

Government-supported R&D project

Venture company certification

2016

Established Medifab corporation

core value

Our Vision

MEDIFAB aims to become a globally recognized leader in medical aesthetics and anti-aging innovation. Grounded in our proprietary ingredient platforms and an expanding network of 50+ partners across Asia, the Middle East, Europe, and North America, we are committed to setting new standards in anti-aging science and bringing the Clinic to Home philosophy to every corner of the world.

CEO

A message from
our CEO

Mi-Sun Cha, CEO

Mi-Sun Cha

CEO

Built on proprietary technologies and ingredient platforms, MEDIFAB is a global anti-aging company that provides total anti-aging solutions.

MEDIFAB will continue to set new standards in regenerative medicine and medical aesthetics.

global network

Global Expansion

Global Partners

50+

Asia · Middle East · Europe · N. America

Greater China

3 live sessions with Xu Shan, KRW 1B+

MOU with Shanghai Yanxinuowei

res novae Core Impact initial export to Taiwan (2026)

Japan

res novae Crystal Plus dealership contract completed

Sales commenced in the second half of 2026

Southeast Asia

Local distributor contracts completed in Thailand and Indonesia

Middle East

Exclusive contracts completed in Middle Eastern countries including UAE and Iraq

Sales commenced in the second half of 2026

Europe · Americas

res novae Crystal Plus contract and licensing completed in Canada; sales expansion in the UK